Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Lenaldekar
Cat. No.:
0225LY-0812
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Lenaldekar prevents T-cell expansion and inhibits autoimmune encephalomyelitis by inducing dephosphorylation within the PI3 kinase/AKT/mTOR pathway and delaying mitosis in sensitive cells.
Synonym:
418800-15-4; 8-[(E)-2-[(1H-indol-3-yl)methylidene]hydrazin-1-yl]quinoline; 1h-indole-3-carbaldehyde 8-quinolinylhydrazone; MFCD00409836
CAS No.:
418800-15-4
Compound CID:
135470799
Formula:
C18H14N4
Formula Weight:
286.33
Specification
Relative Density:
1.26 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Lenaldekar can be used in hematological research or play an important role in the study of AKT-dependent leukemia survival.
Library Information
Target:
Akt; S6 Kinase; IGF-1R
Receptor:
IGF-1R; P-Akt (S473); P-Akt (T308); S6 Kinase
Pathways:
Cytoskeletal signaling; MAPK; Tyrosine kinase/adaptors; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-11
Plate Location:
d11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
55 mg/mL; 192.09 mM
